Yearly Archive

Yearly Archives: 2013

April 8, 2013 no comments

The power of crowds – and their limits

The first internet revolution in the 1990s saw the emergence of on-line service providers who offered the same service as off-line competitors, but cut costs.  Big winners included Amazon and LastMinute.com.

But the second, and arguably bigger, internet revolution in the 2000’s was the emergence of social networks, with Facebook, LinkedIn and Twitter in the vanguard.  These surprisingly simple tools – Facebook is little more than a village noticeboard with millions, rather than dozens, of potential contributors – unlocked the power of the crowd.

Crowds can do some amazing things.  Whether you need to find someone extra smart, or aggregate thousands of tiny contributions to create something huge, virtual crowds organized through social networks have made possible what was previously unthinkable.

And the next target for crowds seems to be funding businesses – and most recently even academic science.

In principle, it sounds like a great idea: a small, almost invisible, contribution from enough people can together deliver enough resources to change the world.  Platforms, like Microryza, are springing up like mushrooms to harness these ‘donations’ and channel them to deserving causes.  “Crowdfunding” is on everybody’s lips.

The key difference with crowdfunding lies in the distributed decision-making capacity, rather than just distributing the cost

Can crowdfunding really shake the foundations of current financing models for biotech companies and for academic science? Or will it remain a niche opportunity dwarfed by conventional funding mechanisms?

DrugBaron predicts that initial excitement and expansion in the sector may rapidly be followed by disappointment and contraction – unless a solution can be found to the quality control issue when the funders cannot be expected to understand the details of the projects they are being asked to fund.

After all, existing public funding of academic science is nothing but “crowdfunding”.  Can social networks really do a better job of distributing our communal investment in research than research councils or even venture capitalists? Crowds can do amazing things, but crowdfunding biotech business or academic research might be a step too far.

More

More
July 23, 2012 no comments

Boehringer Ingelheim and Funxional Therapeutics announce acquisition of Funxional’s FX125L and the somatotaxin portfolio to treat inflammation

Ingelheim, Germany and Cambridge, UK – 23 July …

More
May 17, 2012 no comments

Aiming for Average: Three traits where being best means being bang in the middle

Winning entrepreneurs tend not be average.  On traits …

More
April 9, 2012 no comments

The UK Patent Box: a welcome gift for small biotech as well as large pharma

Confirming the launch of the Patent Box tax …

More
March 21, 2012 no comments

Five Vital Statistics of a Successful Venture Fund – How does the new Index Ventures Life Science Fund Measure up?

The launch of Index Ventures’ new life sciences …

More
January 3, 2012 no comments

New Year, Same Message: Ignore Commercial Risk at your Peril

DrugBaron wishes his readers a Happy New Year.  …

More
December 17, 2011 no comments

Chocolate-flavoured Poison: Like red wine and debt, the company-building model of biotech investing tastes good but kills you eventually

The most dangerous imperatives are those that you …

More
December 5, 2011 no comments

Too Much Skin in the Game?

There are very few rules for the biotech …

More
November 19, 2011 no comments

Choosing the Right Path

Choosing the right path in clinical development – …

More
November 1, 2011 no comments

The End of a Dream for Population Screening as Diagnostic’s “Blockbuster” Product

For a decade investors in the development of …

More

Yearly Archive